Skip to main content

Esma Probes APAs Amid Mifid Trade Data Issues

Approved Publication Arrangements—a critical component in the new Mifid II European markets regulation—may be falling short of their requirements under the new transparency rules, and have drawn Esma’s attention. By Samuel Wilkes, with additional reporting by Lukas Becker

The controversy concerns APAs, which investment firms use to fulfill new pre- and post-trade transparency requirements under Mifid II and its accompanying Mifir regulation, which came into force on January 3. Pre-trade transparency means publishing offered executable quotes, while the price and quantity of certain trades must be published after execution.

The APAs must make the data free and available to the public 15 minutes after execution of the trade, but they can charge users for real-time

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: https://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

Register for free

Access two articles, our IMD and Waters Wraps, plus a member newsletter. Find out more.

All fields are mandatory unless otherwise highlighted.

Show password
Hide password

2026 will be the year agent armies awaken

Waters Wrap: Several AI experts have recently said that the next 12 months will see significant progress for agentic AI. Are capital markets firms ready for this shift from generative AI to agents?

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here